It is curious that most physicians believe that their practices are not influenced by direct-to-physician marketing, yet the pharmaceutical industry continues to spend enormous sums of money – billions of dollars in the US annually – on this activity (1). Clearly, the pharmaceutical companies are seeing a return on their investment in physician marketing (2), though it is in their best interest, and that of physicians, to downplay its impact…
Filed under: Message From the Editor | Tagged: AMA physician masterfile, Avonex, Betaseron, bias, conflict of interest, Copaxone, direct-to-physician marketing, financial disclosure, industry-sponsored research, pharmaceutical marketing, prescribing data, Prescribing Data Restriction Program, Rebif, research grants, sunshine bill | Leave a Comment »
